| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Leerink Partners analyst Marc Goodman downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Outperform to Market Perform and ...
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Buy to Neutral and l...
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...
Jefferies analyst Andrew Tsai downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Buy to Hold and lowers the price target f...
Needham analyst Ami Fadia downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Buy to Hold.